Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
04 1월 2024 - 11:29AM
Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a
clinical-stage biopharmaceutical company focused on developing and
commercializing novel therapeutics to treat a wide range of
patients with disorders that are linked to dysfunctional signaling
of the transforming growth factor-beta (“TGF-ß”) family of
proteins, today announced the pricing of an underwritten public
offering of 3,500,000 shares of common stock, at a public offering
price of $40.00 per share. The gross proceeds to Keros from the
offering, before deducting underwriting discounts and commissions
and offering expenses, are expected to be $140.0 million. All of
the common stock is being offered by Keros. In addition, Keros has
granted the underwriters a 30-day option to purchase up to an
additional 525,000 shares of common stock at the public offering
price, less the underwriting discounts and commissions. The
offering is expected to close on January 8, 2024, subject to
satisfaction of customary closing conditions.
Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler and
Truist Securities are acting as joint book-running managers for the
offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 that was filed with the Securities and
Exchange Commission (“SEC”) on May 3, 2021 and was effective upon
filing. The offering will be made only by means of a prospectus
supplement and the accompanying prospectus which forms a part of
the effective shelf registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering was filed with the SEC on January 3, 2024, and is
available on the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained, when available, by visiting the SEC’s
website or by contacting: Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, NY 10282, by
telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; Leerink Partners LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA
02109, by telephone at 1-800-808-7525, ext. 6105, or by email at
syndicate@leerink.com; Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, by telephone at (800) 747-3924, or by email at
prospectus@psc.com; or Truist Securities, Inc., Attention:
Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta,
GA 30326, by telephone at (800) 685-4786, or by email at
TruistSecurities.prospectus@Truist.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any offer or
sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
developing and commercializing novel therapeutics to treat a wide
range of patients with disorders that are linked to dysfunctional
signaling of the TGF-ß family of proteins. We are a leader in
understanding the role of the TGF-ß family of proteins, which are
master regulators of the growth, repair and maintenance of blood
cells and a number of tissues, including bone, skeletal muscle,
adipose and heart tissue. By leveraging this understanding, we have
discovered and are developing large and small molecules that have
the potential to provide meaningful and potentially
disease-modifying benefit to patients. Keros’ lead protein
therapeutic product candidate, KER-050 (elritercept), is being
developed for the treatment of low blood cell counts, or
cytopenias, including anemia and thrombocytopenia, in patients with
MDS and in patients with MF. Keros’ second product candidate,
KER-012, is being developed for the treatment of pulmonary arterial
hypertension and for the treatment of cardiovascular disorders.
Keros’ third product candidate, KER-065, is being developed for the
treatment of obesity and for the treatment of neuromuscular
diseases.
Cautionary Note Regarding Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as "anticipates," "believes,"
"expects," "intends," “plans,” “potential,” "projects,” “would” and
"future" or similar expressions are intended to identify
forward-looking statements. Examples of these forward-looking
statements include statements concerning: the completion, timing
and size of the proposed offering. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among others:
Keros’ limited operating history and historical losses; Keros’
ability to raise additional funding to complete the development and
any commercialization of its product candidates; Keros’ dependence
on the success of its product candidates, KER-050, KER-012 and
KER-065; that Keros may be delayed in initiating, enrolling or
completing any clinical trials; competition from third parties that
are developing products for similar uses; Keros’ ability to obtain,
maintain and protect its intellectual property; and Keros’
dependence on third parties in connection with manufacturing,
clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Quarterly Report on Form
10-Q, filed with the SEC on November 6, 2023, and its other
documents subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Keros undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:Justin
Frantzjfrantz@kerostx.com617-221-6042
Keros Therapeutics (NASDAQ:KROS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Keros Therapeutics (NASDAQ:KROS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024